Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 16, 2026

Acquisition of Own Shares

Mechelen, Belgium; 15 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 07, 2026 and September 11, 2026 it has repurchased 125,517 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 07/09/2026 XAMS 22,861 24.44 558,763.99 24.20 24.56 07/09/2026 TQEX 1,166 24.43 28,486.20 24.26 24.56 07/09/2026 CEUX 157 24.47 3,842.47 24.44 24.56 08/09/2026 XAMS 23,629 24.23 572,611.01 23.98 24.52 08/09/2026 TQEX 1,705 24.33 41,475.66 24.28 24.38 08/09/2026 CEUX 2,044 24.23 49,533.68 24.00 24.40 08/09/2026 AQEU 492 24.26 11,937.89 24.06 24.36 09/09/2026 XAMS 22,015 23.91 526,444.69 23.64 24.12 09/09/2026 TQEX 527 23.90 12,596.56 23.82 24.02 09/09/2026 CEUX 2,355 23.95 56,410.73 23.84 24.10 09/09/2026 AQEU 914 24.01 21,941.21 23.86 24.08 10/09/2026 XAMS 20,285 23.64 479,622.60 23.24 23.96 10/09/2026 TQEX 827 23.56 19,487.01 23.30 23.92 10/09/2026 CEUX 1,917 23.28 44,631.21 23.26 23.34 10/09/2026 AQEU 984 23.78 23,395.19 23.68 23.92 11/09/2026 XAMS 20,038 23.45 469,987.28 23.20 23.66 11/09/2026 TQEX 492 23.62 11,619.47 23.52 23.64 11/09/2026 CEUX 2,640 23.38 61,727.95 23.20 23.60 11/09/2026 AQEU 469 23.52 11,030.32 23.44 23.62 Total   125,517 23.95 3,005,545.12 23.20 24.56 As of market close on September 11, 2026, Lakefront holds 1,418,855 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

GlobeNewsWire • Sep 15, 2026

Lakefront Biotherapeutics: A Cash Discount With A More Credible Path To Value

Lakefront Biotherapeutics offers valuation support and clinical upside, leveraging a new development model post-Ouro acquisition and partnership with Gilead. LKFT's €2.24 billion liquidity and disciplined capital allocation provide runway through the first gamgertamig approval, with at least €1.6 billion projected post-approval. Gamgertamig's clinical promise targets difficult autoimmune diseases, but durable efficacy, safety, and competitive differentiation remain unproven and critical for future value.

Seeking Alpha • Sep 15, 2026

Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City at 5:35pm ET on Tuesday, September 15 th , 2026.

GlobeNewsWire • Sep 8, 2026

Lakefront Receives Transparency Notification from Bank of America

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

GlobeNewsWire • Aug 24, 2026

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).

GlobeNewsWire • Aug 24, 2026

Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.

GlobeNewsWire • Jul 13, 2026

Lakefront Receives Transparency Notification from Madison Avenue Partners

Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.

GlobeNewsWire • Jun 29, 2026

Lakefront Announces Initiation of €50 Million Stock Repurchase Program

Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.

GlobeNewsWire • Jun 9, 2026

Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

Mechelen, Belgium ; June 8, 2026, 22:01 CET; Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. 1 Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee.

GlobeNewsWire • Jun 8, 2026